Literature DB >> 15737568

Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells.

Marco Folini1, Cinzia Brambilla, Raffaella Villa, Paolo Gandellini, Sara Vignati, Francesco Paduano, Maria Grazia Daidone, Nadia Zaffaroni.   

Abstract

Recent evidence points to a novel function of human telomerase reverse transcriptase (hTERT) in promoting tumour cell survival, which might be independent of the telomere-elongating activity of the enzyme. To test this hypothesis, we evaluated comparatively the effects of telomerase inhibition, accomplished through antisense oligonucleotide-mediated interference with hTERT or human telomerase RNA component (hTERC), on the proliferative potential of DU145 human prostate cancer cells. Exposure of cells to a 2'-O-methyl-RNA phosphorothioate oligonucleotide targeting a splicing site within hTERT pre-mRNA induced almost complete inhibition of telomerase activity as a consequence of a marked reduction of the hTERT mRNA expression level, an early decline of DU145 cell growth and apoptotic cell death without any appreciable telomere shortening. Conversely, exposure of DU145 cells to a 2'-O-methyl-RNA phosphorothioate oligonucleotide targeting the template region of hTERC failed to interfere with cell proliferation in spite of the almost complete abrogation of telomerase activity. These results extend and corroborate earlier evidence in favour of an enzymatic activity-independent mechanism by which hTERT maintains tumour cell survival and proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737568     DOI: 10.1016/j.ejca.2004.12.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Telomerase activity in pleural malignant mesotheliomas.

Authors:  Amy Y M Au; Torben Hackl; Thomas R Yeager; Scott B Cohen; Harvey I Pass; Curtis C Harris; Roger R Reddel
Journal:  Lung Cancer       Date:  2011-01-31       Impact factor: 5.705

2.  Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant.

Authors:  Lisa F Lincz; Lisa-Maree Mudge; Fiona E Scorgie; Jennette A Sakoff; Christopher S Hamilton; Michael Seldon
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

3.  Effect of targeted silencing of hTERT mRNA by lentivirus-mediated siRNA on A549 lung cancer cells in vitro.

Authors:  Haibo Tang; Linhu Ge; Wenlong Shao; Yuan Qiu; Dong Cui
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

4.  Effect of TERT on the growth of fibrosarcoma via caspase-3, survivin and PKB.

Authors:  Qiuye Ma; Yidong Yu; Linlin Dai; Xuehua Qu; Shan Cong; Hongsuo Liang
Journal:  Oncol Lett       Date:  2017-06-13       Impact factor: 2.967

5.  Biological significance of PinX1 telomerase inhibitor in esophageal carcinoma treatment.

Authors:  Xiang-Kui Fan; Rui-Hua Yan; Xiang-Qun Geng; Jing-Shan Li; Xiang-Ming Chen; Jian-Zhe Li
Journal:  Exp Ther Med       Date:  2016-08-01       Impact factor: 2.447

6.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors.

Authors:  Maria Antonietta Avanzini; Maria Ester Bernardo; Angela Maria Cometa; Cesare Perotti; Nadia Zaffaroni; Francesca Novara; Livia Visai; Antonia Moretta; Claudia Del Fante; Raffaella Villa; Lynne M Ball; Willem E Fibbe; Rita Maccario; Franco Locatelli
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

7.  Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands.

Authors:  SunMi L Palumbo; Scot W Ebbinghaus; Laurence H Hurley
Journal:  J Am Chem Soc       Date:  2009-08-12       Impact factor: 15.419

8.  Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer.

Authors:  Z Qi; R Mi
Journal:  Cancer Gene Ther       Date:  2016-01-08       Impact factor: 5.987

9.  Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells.

Authors:  M Folini; R Bandiera; E Millo; P Gandellini; G Sozzi; P Gasparini; N Longoni; M Binda; M G Daidone; K Berg; N Zaffaroni
Journal:  Cell Prolif       Date:  2007-12       Impact factor: 6.831

Review 10.  New prospects for targeting telomerase beyond the telomere.

Authors:  Greg M Arndt; Karen L MacKenzie
Journal:  Nat Rev Cancer       Date:  2016-06-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.